Meta has introduced the Muse Charm, a playful AI device designed as a customizable avatar that doubles as a fashion accessory, targeting Gen Z consumers. This product taps into the growing trend of tech-as-fashion, reminiscent of popular bag charms and retro gadgets, appealing to younger users seeking more tangible, personalized tech experiences. However, Meta's history of privacy issues may challenge consumer trust and adoption. The Muse Charm's success will depend on whether consumers accept Meta's privacy tradeoffs in exchange for free AI services and personalized ads.
Meta's Muse Charm, a new AI fashion accessory, is the story subject with this Pluang market context as of Sep 24, 2026 23:51 WIB: Among 150 priced Technology-sector US stocks tradable on Pluang, 61 rose and 88 fell today. Notable movers include ORCL at USD 139.18 with a 1-day change of -3.71% and Pluang order activity of 84% Sell / 16% Buy, IONQ at USD 44.12 up 3.71% with 42% Sell / 58% Buy, and GPRO at USD 1.26 down 3.44% with 43% Sell / 57% Buy. The most notable figure is ORCL's 84% sell order activity.
Costco reported a strong Q4 earnings per share (EPS) of $6.75, surpassing analyst expectations of $6.54, helped by tariff refunds. Although quarterly revenue of $93.87 billion slightly missed the $94.97 billion forecast, net sales rose 11.2% year-ove...
Vistry Group reported a significant first-half pre-tax loss of £661.3 million, driven by a £475 million goodwill impairment and increased building safety costs. Revenue fell to £1.42 billion, and operational performance weakened with fewer home compl...
Vail Resorts is set to report its Q3 2026 earnings on September 28, with analysts forecasting a loss per share around -$5.30 and revenue near $271 million, indicating flat performance year-over-year. The company’s financial health shows a high Debt-t...
Western Union faces multiple analyst downgrades with price targets cut to as low as $6.00, reflecting concerns over its profitability and competitive pressures from fintech rivals. The stock has fallen over 15% in the past month, trading near $6.00, ...
Citigroup lowered ACADIA Pharmaceuticals' price target from $40 to $33 after its Alzheimer's drug remlifanserin missed the primary goal in a mid-stage trial, causing a 10.5% stock drop. Despite this, Citigroup kept a "Buy" rating, citing promising se...
